Davide Campari-Milano (CPR) Q2 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q2 2025 earnings summary
11 Jun, 2026Executive summary
Net sales for H1 2025 reached €1,528 million, up 0.3% year-over-year, with organic growth of 0.1% and a 2.0% perimeter effect, offset by a -1.8% FX impact; Q2 saw marked improvement and sector outperformance, especially in aperitifs and agave.
Group net profit was €206.4 million, down 6.0% year-over-year, with adjusted net profit at €216.2 million, down 9.5%, reflecting higher brand investments and FX headwinds.
EBITDA-adjusted was €426.6 million (27.9% margin), up 1.9% year-over-year; EBIT-adjusted was €351.8 million (23.0% margin), down 2.3%.
Strategic initiatives advanced, including portfolio streamlining, cost containment, and no major acquisitions planned.
Maintained pricing discipline and commercial excellence despite challenging consumer environments and economic headwinds.
Financial highlights
Gross margin improved to 61.1% of net sales, up 40bps year-over-year, with Q2 acceleration mainly due to input cost phasing and agave price benefits.
Free cash flow was €34.9 million (vs. -€60.1 million in H1 2024); recurring free cash flow at €113 million, with a high conversion rate of 27%.
Net financial debt stood at €2,382 million, stable versus year-end 2024; leverage ratio improved to 3.2x from 3.5x post-Courvoisier acquisition.
Capex investments totaled €82 million, with €39 million in extraordinary capex for capacity expansion.
Dividend of €78 million paid and share buyback of €22 million completed in H1 2025.
Outlook and guidance
Guidance for 2025 confirmed: moderate organic top-line growth and flat EBIT-adjusted margin before tariff impact.
Tariffs could impact EBIT by €4–45 million in 2025, depending on scope and rates; not included in current guidance.
Medium/long-term outlook: return to mid- to high-single-digit organic net sales growth, margin accretion from premiumization and cost efficiencies.
SG&A cost containment on track for 50bps benefit in 2025 and 200bps over three years.
Q3 peak season performance seen as fundamental for full-year visibility; more detailed outlook to be provided in November.
Latest events from Davide Campari-Milano
- Solid H1 2024 growth, Courvoisier acquisition, and higher leverage amid resilient brand momentum.CPR
Q2 202411 Jun 2026 - Net sales up 2.1% organically, but margins and profit fell as costs and debt increased.CPR
Q3 202411 Jun 2026 - Q1 2025 saw flat sales, margin pressure, and higher debt amid macro and tariff headwinds.CPR
Q1 202511 Jun 2026 - Solid organic growth and margin resilience achieved despite macro headwinds, with leverage down to 2.9x.CPR
Q3 202511 Jun 2026 - Q1 2026 delivered +2.9% organic growth, with ~3% full-year guidance and margin gains expected.CPR
Q1 20266 May 2026 - Organic sales up 2.4%, margin expansion, and a 54% dividend increase with improved leverage.CPR
Q4 20254 Mar 2026 - Resilient 2024 growth and strong cash flow, but margin pressures and tariff risks ahead.CPR
Q4 202410 Dec 2025